Analyst Reco. Agenus Inc.

Equities

AGEN

US00847G8042

Real-time Estimate Cboe BZX Other stock markets 10:21:00 2024-05-21 am EDT			5-day change	1st Jan Change
10.74 ^USD	+0.42%		+2.10%	-34.02%

May. 16	Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	CI
May. 07	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	Mar. 18	MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	Nov. 09	MT
Baird Initiates Agenus at Outperform With $8 Price Target	23-06-06	MT
HC Wainwright Assumes Agenus at Buy With $8 Price Target	23-02-28	MT
EF Hutton Starts Agenus With Buy Rating, Sets Price Target at $8.30	22-12-22	MT
EF Hutton Initiates Agenus With Buy Rating, Price Target is $8.3	22-12-08	MT
SMBC Nikko Starts Agenus at Outperform With $5 Price Target	22-09-28	MT
B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating	22-03-03	MT
HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating	22-03-02	MT
HC Wainwright Starts Agenus at Buy With $12 Price Target	21-12-16	MT
Agenus : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 Trial	21-09-17	MT
AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to Drive Stock Price Performance; Keeps Buy Rating	21-09-07	MT
AGENUS : B. Riley Raises Agenus' PT to $11 from $8, Notes Value Accretive Catalysts; Keeps Buy Rating	21-06-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW